Home › trial
 

Keywords :   


Tag: trial

BASF Starts Trial Production of Mononitrobenzene in Chongqing

2015-04-30 07:00:00| Coatings World Breaking News

Tags: production trial starts chongqing

 

Cambridge Semantics And Informa Named Bio-IT Award Finalist For Smart Data Lake Solution For Clinical Trial And Competitive Intelligence

2015-04-29 05:05:34| drugdiscoveryonline Home Page

Cambridge Semantics, the leading provider of smart data solutions driven by Semantic Web technology, and Informa, the leading international provider of specialist information and services for the academic and scientific, professional and commercial business communities, today announced that its joint solution ‘Smart Data Lake for Clinical Trial and Competitive Intelligence’ was named a finalist for the 2015 Bio-IT ‘Best of Show’ Award

Tags: data solution trial lake

 
 

Merck Announces the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Met Primary Endpoint

2015-04-27 23:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) of Mercks DPP-4 inhibitor, JANUVIA (sitagliptin), achieved its primary endpoint of non-inferiority for the composite cardiovascular (CV) endpoint. Among secondary endpoints, there was no increase in hospitalization for heart failure in the sitagliptin group versus placebo. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestor:Joe Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: met primary trial outcomes

 

Merck Announces Presentation of Phase 2 Clinical Trial Results of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir at the International Liver CongressTM 2015

2015-04-25 15:00:00| Merck.com - Corporate News

Dateline City: VIENNA Results of C-SALVAGE Study Showed High Sustained Virologic Response Rates in Patients Who Failed Prior Combination Therapy with Certain Direct Acting Antiviral (DAA) Agents Results of C-SWIFT Study Provide Proof-of-Concept for Shorter Than Twelve Weeks Duration of Treatment with Triple-DAA Regimen in Patients with Chronic Hepatitis C Virus (HCV) Genotypes 1 and 3 Infection VIENNA April 25, 2015 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from two Phase 2 clinical trials evaluating the safety and efficacy of the companys investigational once-daily treatment regimen of grazoprevir (100mg) and elbasvir (50mg)[1] in adult patients with chronic hepatitis C virus (HCV) infection. Language: English read more

Tags: the results international trial

 

Judge Declines To Sever And Stay As Trial Date Approaches

2015-04-25 01:43:26| Electronics - Topix.net

Fairchild Semiconductor Corporation, et al. v. Power Integrations, Inc , C.A. No.

Tags: date stay trial approaches

 

Sites : [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] next »